# Diabetic Macular Edema FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/diabetic-macular-edema

> No upcoming FDA catalysts in diabetic Macular Edema; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 2, 2026 | [Dexamethasone ophthalmic suspension (ocs-01) primary completion](https://sec-api.dev/pdufa/dexamethasone-ophthalmic-suspension-ocs-01) | OCS | Diabetic Macular Edema | completed | "NCT06172257 (A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-02 (ACTUAL); Lead Sponsor Oculis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06172257)) |
| April 10, 2026 | [Dexamethasone ophthalmic suspension (ocs-01) primary completion](https://sec-api.dev/pdufa/dexamethasone-ophthalmic-suspension-ocs-01) | OCS | Diabetic Macular Edema | completed | "NCT05066997 (A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-04-10 (ACTUAL); Lead Sponsor Oculis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05066997)) |
| October 2, 2026 | [BGE-102 trial start](https://sec-api.dev/pdufa/bge-102) | BIOA | diabetic macular edema | completed | "BioAge Labs, Inc. (the "Company") recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema ("DME"), and provided updates on the QUELL-DME Phase 2 trial design." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/bioa-20261002.htm)) |

## Drugs

- [Dexamethasone ophthalmic suspension (ocs-01)](https://sec-api.dev/pdufa/dexamethasone-ophthalmic-suspension-ocs-01) (OCS)
- [BGE-102](https://sec-api.dev/pdufa/bge-102) (BIOA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/diabetic-macular-edema.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Diabetic Macular Edema FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/diabetic-macular-edema

```bibtex
@misc{secapidev_indications_diabetic_macular_edema_20261116,
  title        = {Diabetic Macular Edema FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/diabetic-macular-edema}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_diabetic_macular_edema_20261116","title":"Diabetic Macular Edema FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/diabetic-macular-edema","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
